Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz
|
|
|
|
Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them! |
 |
"2 NEW THERAPIES FOR ALZHEIMER'S"
 |
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury,
Alzheimer's Disease & Cognitive Disorders Clinics;
Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association
St. Joseph's Hospital and Medical Center |
|
|
|
|
|
|
DO YOU HAVE ALZHEIMERS?
|
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....
Stan Swartz, CEO,
The MD Health Channel
|

"You'll receive all medication and study based procedures at
no charge
if you qualify for one of the many trials being conducted at Barrow Neurological Institute." |
|
|
|
|
 |
Patricio Reyes M.D.
Director, Traumatic Brain Injury,
Alzheimer's Disease & Cognitive Disorders Clinics;
Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association
Barrow Neurological Institute
St. Joseph's Hospital and Medical Center |
"PRESERVING BRAIN FUNCTIONS " |
 |
Runtime: 50:22 |
 |
Runtime: 50:22 |
"2 NEW THERAPIES FOR ALZHEIMER'S" |
 |
Runtime: 10:27 |
 |
Runtime: 10:27 |
ALZHEIMER'S AWARENESS PROGRAMS |
 |
Runtime: 5:00 |
 |
Runtime: 5:00 |
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE |
 |
PDF Document 850 kb |

Download Free |
|
|
4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors! |
 |
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute
J.N. Harber Chairman of Neurological Surgery
Professor Section of Neurosurgery
University of Arizona |
TALES OF NEUROSURGERY: |
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
|
Lou Grubb Anurism
|
The young Heros - kids who are confronted with significant medical problems!
|
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
|
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER
|
|
 |
Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic
Barrow Neurological Clinics |
COPING WITH DEMENTIA |
 |
|
 |
|
Free Windows Media Player Click |
|
|
Links |
Barrow Neurological Institute |
|
Archives |
October 2006 |
November 2006 |
December 2006 |
January 2007 |
February 2007 |
March 2007 |
May 2007 |
June 2007 |
November 2007 |
December 2007 |
April 2008 |
July 2008 |
August 2008 |
September 2008 |
October 2008 |
November 2008 |
December 2008 |
January 2009 |
February 2009 |
March 2009 |
April 2009 |
May 2009 |
February 2010 |
March 2013 |
May 2013 |
November 2013 |
January 2014 |
February 2014 |
March 2014 |
April 2014 |
May 2014 |
June 2014 |
July 2014 |
June 2016 |
July 2016 |
August 2016 |
September 2016 |
October 2016 |
November 2016 |
December 2016 |
January 2017 |
February 2017 |
March 2017 |
April 2017 |
May 2017 |
June 2017 |
July 2017 |
August 2017 |
September 2017 |
October 2017 |
November 2017 |
December 2017 |
January 2018 |
February 2018 |
March 2018 |
April 2018 |
May 2018 |
June 2018 |
July 2018 |
August 2018 |
September 2018 |
October 2018 |
November 2018 |
December 2018 |
January 2019 |
February 2019 |
 |
Sunday, June 25, 2017
Mutation Contributes to Faster Progression of Alzheimer’s Disease, Study Reports

A mutation in the BDNF gene can accelerate loss of memory and cognitive function in people at risk of developing Alzheimer’s, according to a study.
The study, “BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer’s Prevention,” was published in the journal Neurology.
BDNF is an important neurotransmitter in the brain, playing a role in both neuron signaling and survival. The mutation of the gene is known as the BDNF Val66Met allele, or simply the Met allele.
“We found that people with Alzheimer’s risk who have this BDNF gene mutation called the Met allele may have a more rapid decline of memory and thinking skills,” Dr. Ozioma Okonkwo, the author of the study, said in a news release. “Because this gene can be detected before the symptoms of Alzheimer’s start, and because this presymptomatic phase is thought to be a critical period for treatments that could delay or prevent the disease, it could be a great target for early treatments.”
Researchers wanted to see how many of the 1,023 people enrolled in the Wisconsin Registry for Alzheimer’s Prevention had the Met allele. The mean age of the enrollees was 55.
The team tested the patients’ memory and cognitive skills. They also tested 140 for beta-amyloid protein aggregates in the brain, a hallmark of Alzheimer’s disease.
Thirty-two patients carried the Met allele, researchers discovered. Their memory and cognitive function declined faster than those without the mutation, according to tests the team conducted.
Patients with both the Met allele and beta-amyloid accumulation experienced even greater memory and cognitive decline.
The results suggest that the Met allele plays an important role in cognitive decline and could become a target for therapies that prevent or slow the development of Alzheimer’s.
Story
Source: The
above story is based on materials provided by ALZHEIMERSNEWSTODAY
|